Day One Biopharmaceuticals, Inc. (DAWN)
| Previous close | 16.62 |
| Open | 17.13 |
| Bid | 16.60 x 600 |
| Ask | 16.70 x 100 |
| Day's range | 16.60 - 17.14 |
| 52-week range | 9.67 - 18.07 |
| Volume | |
| Avg. volume | 1,100,729 |
| Market cap | 1.455B |
| Beta (5Y monthly) | -1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.50 |
GlobeNewswireDay One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its f
GuruFocus.comInsider Sale at Day One Biopharmaceuticals Inc (DAWN)
York Charles N II, the COO, CFO, and Secretary of Day One Biopharmaceuticals Inc (NASDAQ:DAWN), sold 60,461 shares of the company on May 3, 2024.
- GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51% Day One receives rare pediatric disease priority review voucher Conference call and webcast to be April 24, 8:30 a.m. Eastern Time BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceuti
